6.2 Novo Nordisk + Septerna (May 2025, up to $2.2B) Novo's second major triple-agonist transaction was a broader small-molecule GPCR collaboration with Septerna announced May 2025: up to $2.2 billion total deal value, $200 million+ upfront, covering four oral small-molecule GPCR programs
Cell (2021) 184(17):446479 e19
Interestingly, retrospective analysis on obese and diabetic patients revealed a chemo-preventive potential of bariatric surgery or treatment with anti-diabetic and/or anti-hypertension medicaments with risk reduction of PDAC development [34,35,36]
The relationship between fatty acid compositional changes in plasma and the regression of the damaged aorta luminal area was also analyzed
Gastroenterology guidelines therefore do not recommend docusate as a first-line treatment when more effective options are available., How long does constipation last on GLP-1 medications
The label does not describe or approve maintenance below 1.7 mg (FDA Wegovy label)